Core Viewpoint - Pacira BioSciences, Inc. has received a Paragraph IV Certification Notice Letter from Qilu Pharmaceutical, indicating Qilu's intent to file a generic version of EXPAREL, which may challenge Pacira's patent rights [1][2]. Company Overview - Pacira BioSciences is focused on delivering innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [5]. - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications, utilizing a unique multivesicular liposome technology [6]. Patent and Legal Context - Qilu Pharmaceutical claims that 18 patents related to EXPAREL are invalid or unenforceable, which could allow them to market a generic version [2]. - The contested patents belong to two families, with expiration dates in 2041 and 2044 [3]. - Pacira has 45 days to respond to the PIV Notice and may file a lawsuit to protect its intellectual property, which would trigger a 30-month stay on FDA approval for Qilu's ANDA submission [4].

Core Insights - Pacira BioSciences, Inc. is presenting real-world evidence on the clinical effectiveness and economic benefits of EXPAREL at the AMCP Nexus 2025 Annual Meeting [1][3] - The company aims to advance understanding of postsurgical pain management and reduce reliance on opioids through multimodal pain pathways [3] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [5] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications [5][6] - The company is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [5] Research Presentations - The AMCP Nexus 2025 will feature presentations on the impact of liposomal bupivacaine on healthcare resource utilization and costs in total knee arthroplasty [4] - Additional presentations will cover outcomes related to intraoperative liposomal bupivacaine and its effects on opioid use and functional outcomes [7] Product Details - EXPAREL utilizes multivesicular liposome technology to deliver bupivacaine over time, achieving significant reductions in cumulative pain scores and opioid consumption [8] - The product is indicated for postsurgical local and regional analgesia in patients aged 6 years and older [6]

Core Viewpoint - Pacira BioSciences, Inc. has received a Paragraph IV Certification Notice Letter from The WhiteOak Group, which has filed an Abbreviated New Drug Application for a generic version of EXPAREL, claiming that the patents are invalid or not infringed [1][2] Patent and Legal Context - WhiteOak alleges that 19 patents related to EXPAREL are invalid, unenforceable, or will not be infringed by their product [2] - The contested patents are from two families, with expiration dates of January 22, 2041, and July 2, 2044 [3] - Pacira has 45 days to file a lawsuit to protect its intellectual property rights, which would trigger a 30-month stay of FDA approval for WhiteOak's ANDA submission [4] Company Overview - Pacira specializes in non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera° [5] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications, significantly reducing opioid consumption by up to 78% [6]

Core Insights - Pacira BioSciences, Inc. is set to present new data from its Phase 1 clinical trial of PCRX-201, a gene therapy for knee osteoarthritis, at the ACR Convergence 2025 meeting [1] - A Phase 2 study, known as the ASCEND study, is currently ongoing for PCRX-201 [2] Group 1: Clinical Data and Efficacy - PCRX-201 has shown sustained improvements in knee pain, stiffness, and function over two years in a Phase 1 study involving 72 patients, with a well-tolerated safety profile [4] - The therapy has received RMAT designation from the FDA and ATMP designation from the EMA, marking it as the first gene therapy to achieve such results in knee osteoarthritis [4] Group 2: Technology and Platform - The high-capacity adenovirus vector platform acquired from GQ Bio Therapeutics enables efficient gene delivery, addressing challenges in gene therapy for common diseases like osteoarthritis [5] - The HCAd vector can carry up to 30,000 base pairs of DNA, allowing for the potential administration of multiple or larger genes compared to traditional AAV vectors [6] Group 3: Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products including EXPAREL, ZILRETTA, and iovera [6][7] - The company is advancing PCRX-201 as a locally administered gene therapy aimed at treating prevalent diseases such as osteoarthritis [7]

Core Viewpoint - PharmaCorp RX Inc. has filed its Final Short Form Base Shelf Prospectus, allowing the company to raise up to $100 million through various securities over a 25-month period, enhancing its capacity for strategic acquisitions and growth [2][3]. Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [5]. - The company operates seven pharmacies under the PharmaChoice Canada banner and aims to expand its network by acquiring both bannered and independent pharmacies across Canada [5]. Financial Strategy - The Prospectus enables PharmaCorp to qualify the distribution of common shares, preferred shares, warrants, debt securities, subscription receipts, units, or any combination thereof [2]. - The specific terms of any future offerings will be determined in a Prospectus supplement, which will be filed with Canadian securities regulatory authorities [2]. Growth and Expansion Plans - The filing of the Prospectus is seen as a significant step in PharmaCorp's growth journey, providing the flexibility to access capital efficiently for strategic acquisitions and expansion opportunities [3]. - The company is positioned to accelerate its national growth strategy and strengthen its operational platform through its alliance with PharmaChoice Canada [3].

Core Viewpoint - PharmaCorp RX Inc. has restated and refiled its financial statements for the interim period ended June 30, 2025, following a review by its Auditor, with certain accounting adjustments made that do not affect the overall financial position of the Corporation [1]. Financial Adjustments - The Amended Q2 2025 Statements show significant changes, including an increase in intangible assets from $4,847,651 to $6,937,651 and the addition of an acquired charter valued at $2,090,000 [2]. - The purchases of property and equipment were adjusted from $2,145,438 to $55,438, indicating a significant revision in asset reporting [2]. - The total assets and net cash used in investing activities remained unchanged despite these adjustments, indicating minimal impact on the overall financial health [3]. Notes and Revisions - Changes were made to the notes of the Amended Q2 2025 Statements, including a working capital adjustment for the acquisition of Atlantic Canada 1 amounting to $1,019,014 and the addition of the acquired charter as a line item [5]. - A footnote was added to clarify ownership restrictions under Ontario's Drug and Pharmacies Regulation Act, and amortization amounts were revised accordingly [5]. - Subsequent event notes were added to reflect the closing of the purchase of two pharmacies in Western Canada and one in Eastern Canada, as announced on October 2, 2025 [5]. Company Operations - PharmaCorp operates seven PharmaChoice Canada bannered pharmacies and plans to continue acquiring more pharmacies under this brand, as part of its strategic alliance with PharmaChoice Canada [4]. - The Corporation is also open to acquiring independently owned pharmacies and transitioning them to the PharmaChoice Canada banner [4]. - PharmaCorp actively seeks discussions with pharmacy owners regarding succession or sale, emphasizing a commitment to seamless transitions that protect legacies and serve communities [6].

Core Insights - PharmaCorp RX Inc. has completed the acquisition of three community pharmacy businesses, enhancing its presence in both Western and Eastern Canada [1][4] Western Canada Acquisitions - The company acquired two PharmaChoice Canada bannered pharmacies in Western Canada for an aggregate purchase price of $3,400,000, with 75% paid in cash and 25% through the issuance of common shares [2] - The common shares were priced based on the volume weighted average trading price on the TSX Venture Exchange over a specified period prior to the closing date [2] Eastern Canada Acquisition - PharmaCorp also acquired a PharmaChoice Canada bannered pharmacy in Eastern Canada for $5,300,000, funded through cash on hand and available credit [3] - No finder's fees were incurred in connection with these acquisitions [3] Strategic Growth - The acquisitions are part of PharmaCorp's disciplined growth strategy and strengthen its strategic alliance with PharmaChoice Canada [4] - The company aims to expand its national footprint while preserving independent legacies and ensuring continuity of care for patients [4] - PharmaCorp plans to remain active in pursuing further acquisitions in the near future [4] Company Overview - PharmaCorp currently operates seven PharmaChoice Canada bannered pharmacies and intends to continue acquiring both PharmaChoice and independently owned pharmacies [5] - The company is open to discussions with pharmacy owners considering succession or sale, emphasizing a commitment to seamless transitions [6]

Core Viewpoint - PharmaCorp RX Inc. has filed a preliminary short form base shelf prospectus to qualify the distribution of up to $100 million in various securities over a 25-month period, enhancing its ability to access capital markets for growth and acquisitions [2][3]. Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [5]. - The company operates four pharmacies under the PharmaChoice Canada banner and aims to acquire more pharmacies, rebranding them under its platform [5]. Financial Strategy - The base shelf prospectus will allow PharmaCorp to issue common shares, preferred shares, warrants, debt securities, subscription receipts, units, or any combination thereof, based on financial requirements and market conditions [2]. - The specific terms of any offerings will be detailed in prospectus supplements filed with Canadian securities regulatory authorities [2]. Corporate Development - The filing of the base shelf prospectus is seen as a milestone in PharmaCorp's corporate development, providing flexibility to access capital markets as acquisition opportunities arise [3]. - The strategic alliance with PharmaChoice Canada is highlighted as a key factor in advancing the company's national growth and operations platform [3].

Acquisition Overview - PharmaCorp has signed a definitive share purchase agreement to acquire a 100% interest in a PharmaChoice Canada bannered pharmacy business in Ontario for a purchase price of $5,300,000, expected to close around October 1, 2025 [2][3] - The company has also entered into a non-binding letter of intent to acquire two additional pharmacies in Atlantic Canada for an aggregate purchase price of approximately $6,480,000 [4][5] Strategic Importance - This acquisition is a significant milestone for PharmaCorp as it represents the first transaction completed under its charter company structure established earlier in 2025 [3] - The acquisition strategy is supported by a Strategic Alliance Agreement with PharmaChoice Canada, which is expected to enhance the company's growth and operational capabilities [3][8] Financial Details - The funding for the Ontario acquisition will be sourced from cash on hand and available funds under the corporation's credit facility [2] - The proposed acquisition in Atlantic Canada will be financed through a combination of cash, issuance of common shares, and funds from the credit facility [5] Progress on Previous Transactions - PharmaCorp has successfully closed or entered into definitive agreements for three out of four pharmacies previously announced in May 2025, with an aggregate purchase price of approximately $11,100,000 [9] - The fourth transaction, valued at approximately $1,400,000, will not proceed following due diligence [9] Future Outlook - The company remains committed to expanding its national footprint through strategic acquisitions and aims to deliver long-term value to shareholders [8]

Core Viewpoint - PharmaCorp RX Inc. has entered into definitive share purchase agreements to acquire a 100% interest in two PharmaChoice Canada pharmacies in Western Canada for an aggregate purchase price of $3,400,000 [1][2]. Acquisition Details - The purchase price will be satisfied with 75% cash and 25% through the issuance of common shares, with the share price based on the volume weighted average trading price over a specified period [2]. - The acquisitions are expected to close around October 1, 2025, pending customary closing conditions [3]. Strategic Implications - The transactions demonstrate PharmaCorp's capability to execute accretive acquisitions, aligning with its strategic alliance with PharmaChoice Canada [4]. - PharmaCorp currently operates four PharmaChoice Canada pharmacies and plans to continue acquiring more pharmacies under this brand [4].